Rheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasound by unknown
RESEARCH ARTICLE Open Access
Rheumatoid arthritis patients with
fibromyalgic clinical features have
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Abstract
Background: In patients with rheumatoid arthritis (RA) clinical measures of disease activity may not reliably discriminate
between patients with active inflammatory disease and those with concomitant fibromyalgia (FM). Recent work has
shown RA patients with a 28 tender joint count (TJC) minus swollen joint count (SJC) of 7 or more (joint count criteria)
are more likely to meet classification criteria for FM. This study aimed to determine whether RA patients meeting clinical
criteria for FM had lower levels of joint inflammation as determined by ultrasound (US).
Methods: RA patients with DAS28 > 2.6 were recruited. Patients underwent clinical assessment including ultrasound
examination of the hands and wrists with quantification of grey scale (GS) and power Doppler (PD) synovitis. Patients
completed questionnaires to assess pain, fatigue, disability and psychological comorbidity.
Results: Patients meeting either of the FM criteria had higher scores for disease activity, depression, disability and
fatigue. Those meeting both the joint count and classification FM criteria had significantly lower levels of GS and
PD inflammation on US.
Conclusions: RA patients with concomitant FM, as determined by widespread soft tissue tenderness but fewer
clinically inflamed joints, have higher disease activity scores but may have lower levels of synovial inflammation
on US. This has implications for the identification and management of these patients who may not respond to
conventional therapy and hence be more suitable for alternative approaches to treatment.
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Background
Rheumatoid Arthritis (RA) is a chronic inflammatory
arthritis which, if untreated, can lead to progressive joint
damage, disability, and reduced quality of life. Evidence
suggests that the a ‘treat to target’ approach achieves
better outcomes [1]. The frequently used twenty-eight joint
disease activity score (DAS28) includes both objective
and subjective measures and hence non-inflammatory
factors contribute to patient-reported measures, pain
and tenderness.
Fibromyalgia (FM) is a condition characterized by
chronic widespread pain and tender points on clinical
examination. In the majority of patients, it is associated
with psychological comorbidity, sleep disturbance, fa-
tigue and other somatic symptoms which are reflected
in recently proposed diagnostic criteria [2]. An estimated
20 % of patients with RA have co-existing fibromyalgia
[3]. The presence of concomitant FM can make treat-
ment decisions challenging, as disease activity scores can
be high despite limited clinical evidence of active synovitis
[4]. As the DAS28 cannot distinguish these two groups of
patients who require different treatment pathways, it is
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important to ascertain other discriminatory measures. It is
unknown whether clinical criteria, including those for FM,
are sufficient to discriminate those with active from those
with inactive disease.
Recent work [5] has suggested that a tender joint
count from 28 (TJC) minus swollen joint count (SJC) of
at least 7 (joint count criteria) predicts with high sensi-
tivity and specificity RA patients who also meet 1990
ACR FM classification criteria (tender point criteria). It
is currently unknown whether the joint count or tender
point count can differentiate patients with RA with
genuinely lower inflammatory disease activity and hence
be used to guide treatment decisions.
The aim of this pilot study was therefore to determine
if RA patients with similar clinical disease activity
assessed by DAS28 with clinical features of FM, as de-
fined by the tender joint criteria have lower levels of
joint inflammation compared with RA patients without
FM as determined by US.
Methods
Participants
Patients meeting either the 1987 ACR or the 2010 ACR/
EULAR 2010 RA classification criteria with DAS28(ESR)
> 2.6 were recruited. Patients were categorized into those
meeting or not meeting the joint count criteria i.e., TJC
minus SJC ≥7, or TJC minus SJC < 7. Patients were
recruited sequentially until approximately equal numbers
were recruited to each group.
Ethical approval
Research ethics committee approval was obtained from
the Greenwich REC (# 234567) prior to commencing the
study. The study was carried out according to the princi-
ples of Good Clinical Practice. All participants provided
written informed consent.
Assessments
Patients underwent clinical assessment including 28
tender/swollen joint count with ESR (DAS28) and assess-
ment of soft-tissue tender points. The examining phys-
ician recorded the Symptom Severity Score (SSS). Patients
completed a series of questionnaires including PHQ9
(depression), GAD7 (anxiety), PHQ15 (somatisation),
FACIT-fatigue (fatigue), HAQ (disability), global assessment
visual analogue scale, and the Widespread Pain Index (WPI).
Patients underwent ultrasound examination by a second
physician blinded to the results of the clinical assessment.
US was carried out in a darkened room, in a seated po-
sition with hands prone. Scanning was performed using
Logic 9 (GE Healthcare) scanner with an 14 MHz trans-
ducer. US views were taken using standardised transducer
orientation, taking longitudinal images of the MCPs, PIPs,
and wrists (radiocarpal, ulnar carpal and intercarpal). PRF
was set at 1.4KHz and PD gain was set to just below the
threshold where PD signal disappeared. Grey scale (GS)
still images and 3 s PD images were recorded. A semi
quantitative score was used to grade GS and PD for each
joint (0 no GS or PD signal, 1 =minimal, 2 =moderate, 3
= severe) according to validated criteria [5] and a total
derived for each patient for each of GS and PD.
Analysis
Statistical analysis was carried out using SPSS version 22
(IBM). Descriptive statistics (mean, standard deviation
and confidence intervals) were used for patient characte-
ristics. PD and GS ultrasound score differences between
groups were tested using the Mann–Whitney U test. Sig-
nificance was set at p < 0.05. Mann–Whitney U tests were
used to compare difference between patient reported out-
come measures between the two groups.
Results
Forty-seven patients with active RA on disease-modifying
therapy were recruited. The patient characteristics are
shown in Table 1. The mean age of the patients was 61;
81 % were women, and 70 % were positive for rheumatoid
factor. Mean DAS28 of the patients was 4.5, with 43 %
with moderate disease activity (DAS28 > 3.2 and <5.1),
and 36 % with high disease activity (DAS28 > 5.1). The
mean HAQ was 1.5 (range 0.25-2.5).
Forty percent of patients fulfilled the ACR 1990 Classi-
fication Criteria (CC) and/or the 2010 preliminary diag-
nostic criteria (DC) for fibromyalgia with 25 % meeting
both criteria. 53 % of patients had TJC minus SJC ≥ 7
thus meeting the ‘joint count’ criteria and 36 % of
patients met both ‘joint count’ and ‘classification’ criteria.
Mean DAS28 scores were significantly higher for
patients meeting versus those not meeting FM classifica-
tion criteria, with scores of 5.23 (SD 0.75) and 4.11 (1.0)
respectively (p < 0.001). Mean DAS28 scores were also
significantly higher for patients meeting versus not meet-
ing the tender joint count with scores of 4.99 (0.97) and
4.03 (1.0) respectively (p = 0.002). Tender joint counts
were also significantly higher in patients meeting the FM
classification criteria versus those not meeting criteria
15.66 (5.84) and 7.39 (5.40) respectively (p < 0.001). Ten-
der joint counts were also higher in patients meeting the
tender joint count criteria versus those not meeting cri-
teria with mean tender joint counts of 15.15 (5.21) and
5.24 (4.17) respectively. Patient global scores were numer-
ically higher for patients meeting FM classification criteria
versus those not meeting criteria with scores of 57.05
(18.31) and 49.50 (20.52) respectively, however these did
not reach significance (p = 0.23). The same was true for
patient global scores for patients meeting versus not meet-
ing the tender joint criteria with scores of 56.42 (18.45)
and 47.76 (20.82)(p = 0.13). There were no significant
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differences in swollen joint counts or ESR. These results
are shown in Table 1.
GS US scores were significantly lower in patients meet-
ing either the FM classification or joint count criteria and
for patients that fulfilled both criteria. PDUS scores for pa-
tients meeting either of these criteria were numerically
lower but did not meet significance. However, patients
who met both FM classification and joint count criteria
had significantly lower PDUS scores (2.94, FM group vs
8.33, non-fibromyalgic group, p = 0.028) than those mee-
ting a single fibromyalgia criteria or none. When the 2010
ACR preliminary diagnostic FM criteria were used, no dif-
ferences were seen in US scores or other objective or sub-
jective clinical measures except higher DAS28 scores and
tender joint counts.
Significantly higher levels of fatigue (GAD7), depression
(PHQ9) and disability (HAQ) were also seen in patients
meeting either the joint count or classification criteria
(Table 2). Scores for somatic symptoms and fatigue were
not significantly different.
Discussion
Around 20 % of patients with RA may have concomitant
fibromyalgia [3]. A number of studies have shown that RA
patients with comorbid fibromyalgia, in most cases as de-
fined as widespread pain with soft tissue tenderness, tend
to have higher disease activity scores despite less objective
evidence of active inflammatory disease [4]. This suggests
that conventional disease activity scores may not be able to
differentiate patients with differing causes of high DAS28
scores to allow selection of optimal treatment strategies.
Patients with generalized pain driven by non-inflammatory
mechanisms are unlikely to respond to therapies focused
on suppressing inflammation. In our study median DAS28
scores were higher in patients meeting all definitions of
fibromyalgia, an effect mainly driven by differences in the
tender joint count.
Is has been reported that a TJC minus SJC score greater
than ≥ 7 (‘joint count’ criteria) identifies RA patients who
are more likely to meet the 1990 ACR classification cri-
teria for fibromyalgia, who score highly for disability, de-
pression and fatigue [3]. This is supported by further data
showing psychological distress and poor quality sleep, re-
duce pain thresholds in people with RA [3]. Psychological
distress is predictive of the development of FM in patients
with early inflammatory arthritis [6, 7]. Within the group
of RA patients with concomitant FM and active disease
defined by DAS28, but limited objective evidence of joint
inflammation, it is unclear whether clinical measures can
differentiate those with active synovial inflammation from
those without.
PDUS is more sensitive than clinical examination for
the presence of inflammation [8]: it is predictive of out-
comes in RA and is hence increasingly used in clinical
practice to inform treatment decisions [9]. It therefore
has the potential to help to differentiate patients with
joint pain secondary to generalised widespread pain
from those with active synovial inflammation.
In this study we did not find a significant difference in
PDUS scores between the FM versus non FM patients
when the tender joint criteria were used. It is well-
established that active synovitis can be demonstrated by
PD in joints which are not clinically swollen [10] and so
this may not be surprising. Furthermore, no significant
differences were seen when either the 1990 classification
or 2010 diagnostic criteria were used alone. Neither of the
latter have been validated in the RA patient population.
The identification of widespread non-inflammatory pain
does not preclude the presence of active synovial inflam-
mation so this is not an unexpected finding. A recent
study comparing GS and PDUS findings in RA patients
meeting or not meeting the 2010 diagnostic criteria for
FM found no difference in total GSUS or PDUS scores of
a panel of 7 joints [11]. The diagnostic criteria for FM
Table 1 Patient characteristics




P TP ≥11 (ACR
1990 criteria)
TP <11 P Fulfil both ACR 1990
and TJC criteria
Do not meet both
TJC and ACR criteria
P
n = 26 n = 21 n = 19 n = 28 n = 17 n = 30
Age (SD) 57 66 57 63 57 63
Sex F (%) 22 (85) 16 (76) 16 (84) 22 (79) 15 (88) 24 (80)
RFa (%) 16 (62) 17 (81) 10 (53) 23 (82) 9 (53) 24 (80)
DAS28 (SD) 4.99 (0.97) 4.03 (1.00) 0.002 5.23 (0.75) 4.11 (1.00) <0.001 5.27 (0.68) 4.16 (1.07) <0.001
TJ (SD) 15.15 (5.21) 5.24 (4.17) <0.001 15.663 (5.84) 7.39 (5.40) <0.001 16.47 (5.52) 7.47 (5.26) 0.002
SJ (SD) 1.50 (1.99) 3.52 (3.82) 0.67 1.84 (2.29) 2.79 (3.51) 0.44 1.71 (2.14) 2.80 (3.48) 0.457
ESR (SD) 18.96 (14.79) 20.67 (18.53) 0.94 20.53 (14.44) 19.18 (17.84) 0.38 18.35 (10.99) 20.50 (18.92) 0.157
PG (SD) 56.42 (18.45) 47.76 (20.82) 0.13 57.05 (18.31) 49.50 (20.52) 0.23 59.65 (17.50) 48.53 (20.18) 0.487
amissing data for one patient
Figures given as means and SD
DAS28 twenty-eight joint disease activity score, SJC swollen joint count, SJ swollen joints, TP tender points, TJC tender joint count, TJ tender joints, PG patient
global, RF rheumatoid factor
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include assessment of fatigue, cognitive symptoms, sleep
quality and somatization. However, RA patients score
higher for poor sleep quality, fatigue, cognitive and so-
matic symptoms than controls [12, 13], which are predict-
ive of worse symptoms overall in RA patients regardless of
the presence of FM [14]. It is therefore not surprising that
the FM diagnostic criteria alone lack sensitivity for FM in
a population with RA. Our findings support the view that
the DAS28 may lack sensitivity for inflammatory activity
where there is little or no joint swelling, and therefore
there may be a role for the use of US to guide treatment
decisions.
We showed that FM classification criteria or joint
count criteria alone did not differentiate patients with
higher vs. lower PDUS scores, but when combined they
were able to differentiate patients with lower ultrasound
scores. This supports our suggestion that more rigorous
composite criteria, defining both the presence of wide-
spread pain and limited clinical inflammatory disease
activity, are necessary to differentiate patients with lower
US scores. Our findings that RA patients meeting the
FM classification or joint count criteria scored more
highly for depression, fatigue, somatic symptoms and
disability, replicates that of previous studies. We suggest
that patients with fibromyalgia, RA and high DAS28
scores could be identified by more a comprehensive
assessment incorporating clinical examination, serology
and patient-reported outcome measures.
More accurate stratification of the subgroup of pa-
tients with RA and non-inflammatory widespread pain
could help optimise treatment decisions. If the causes
of symptoms and signs in this difficult to define group
can be clearly identified, it will allow the increasingly
useful therapies for fibromyalgia or inflammatory arth-
ritis to be used with greater precision [15]. Impor-
tantly, therapies for FM are also effective in RA
patients [16] and these strategies may thus help more
sophisticated stratification of patients into different
treatment regimens.
Our study has several limitations. Only the hands and
wrists were assessed by US whereas inclusion of other
joints may provide additional information. It is unclear
how many and which joints should be included and it may
be that a larger panel of joints would have produced differ-
ent results. The number of patients included in this study
was relatively small and these findings need to be repli-
cated in a bigger sample. A larger study is underway in our
centre to determine whether multiple clinical measures of
disease activity and patient-reported measures of other
factors which may be associated with widespread non-
inflammatory pain can better differentiate these groups.
Conclusion
This preliminary study has shown that composite clinical
tools may help to differentiate patients with RA and con-
comitant fibromyalgia with DAS28 > 2.6 who have lower
ultrasonographic disease activity. These patients are less
likely to respond to escalation of inflammation-suppressing
therapy and may be more suitable for other forms of treat-
ment including alternative means of pain control and psy-
chological support. Further work is needed to determine
whether clinical criteria can be used as predictive tools to
identify these patients or whether imaging is necessary for
accurate stratification. We are currently undertaking a larger
study exploring correlation between multiple clinical para-
meters and ultrasonographic measures of inflammation.
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P TP ≥11 (ACR 1990
classification criteria)
TP <11 P Fulfil both ACR 1990
and joint count criteria
Do not meet both joint
count and ACR criteria
P
n = 26 n = 21 n = 19 n = 28 n = 17 n = 30
GAD7 7.58 3.62 0.005 7.84 4.43 0.001 7.71 4.73 0.020
PHQ9 9.27 4.52 0.017 10.89 4.61 0.000 10.59 5.20 0.027
PHQ15 10.77 6.90 0.019 11.79 7.18 0.226 11.88 7.43 0.230
HAQ 1.70 1.27 0.070 1.84 1.29 0.002 1.85 1.32 0.005
FF 25.85 15.81 0.461 27.47 17.21 0.332 28.29 17.43 0.725
WPI 7.15 4.81 0.145 9.47 4.25 0.073 9.41 4.62 0.886
SSS 7.50 4.95 0.699 7.53 5.14 0.316 7.65 5.23 0.494
SJC swollen joint count, TJC tender joint count, TP tender points
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